Opaleye Management Inc., Opaleye, L.P., and James Silverman filed a Schedule 13G with the SEC on November 20, 2026, disclosing beneficial ownership of 5,000,000 ordinary shares of OKYO Pharma Ltd as of November 16, 2026.

Key Highlights

  • Three reporting persons: Opaleye Management Inc., Opaleye, L.P., and James Silverman each report beneficial ownership of 5,000,000 ordinary shares of OKYO Pharma Ltd.
  • Ownership percentage: The 5,000,000 shares represent 9.53% of the class, based on 52,479,527 ordinary shares outstanding as of July 15, 2026.
  • No sole voting or dispositive power: Each reporting person reports 0 shares with sole voting power and 0 shares with sole dispositive power; all 5,000,000 shares are held with shared voting and shared dispositive power.
  • Direct holder: According to the filing, Opaleye, L.P. directly holds the 5,000,000 ordinary shares and has the right to receive dividends from and proceeds from the sale of the reported securities.
  • Triggering event date: The date of the event requiring the filing is listed as November 16, 2026.
  • Certification: The filing certifies that the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

Opaleye Group Reports Passive 9.53% Position in OKYO Pharma Ordinary Shares

According to the Schedule 13G filed on November 20, 2026, three related reporting persons jointly disclosed a beneficial ownership position in OKYO Pharma Ltd (NASDAQ:OKYO). The filing names Opaleye Management Inc., a Massachusetts-incorporated investment adviser; Opaleye, L.P., a Delaware limited partnership that directly holds the shares; and James Silverman, identified as the controlling person of Opaleye Management Inc. All three are addressed at One Boston Place, 26th Floor, Boston, MA 02108.

The filing states that Opaleye, L.P. directly holds 5,000,000 ordinary shares, without par value, of OKYO Pharma Ltd. Opaleye Management Inc., as investment adviser to the Fund, and Mr. Silverman, as the controlling person of the Adviser, "may be deemed to beneficially own such Ordinary Shares," according to the filing. The 5,000,000 shares are reported as 9.53% of the class, calculated using the figure of 52,479,527 ordinary shares outstanding as of July 15, 2026, as reported by OKYO Pharma Ltd in its Form 20-F filed with the SEC on July 20, 2026.

The filing further states that the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing also includes a note that "the filing of this statement shall not be construed as an admission that any Reporting Person is the beneficial owner of any securities covered by this statement for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or otherwise." A Joint Filing Agreement among the reporting persons is attached as Exhibit 99.1.

What Was Disclosed

Opaleye Management Inc., Opaleye, L.P., and James Silverman filed a Schedule 13G disclosing beneficial ownership of 5,000,000 OKYO Pharma Ltd ordinary shares, representing 9.53% of the class, with the triggering event dated November 16, 2026.